Moderna announced agreement with Switzerland for 7 million booster vaccine doses in 2022 with options
On May 6, 2021, Moderna announced a new supply agreement with the Swiss Federal Government for 7 million…
-
-
Novavax and Gavi executed advance purchase agreement for COVID-19 vaccine for COVAX facility
On May 6, 2021, Novavax announced that it had finalized an advance purchase agreement (APA) with Gavi, the…
-
CytoDyn reaches agreement with Albert Einstein Israelite Hospital in Brazil to conduct two COVID-19 trials
On May 5, 2021, CytoDyn announced an agreement to partner with the Albert Einstein Israelite Hospital (AEIH) in…
-
Moderna announced positive initial booster data against SARS-CoV-2 variants
On May 5, 2021, Moderna announced initial data from its Phase 2 study showing that a single 50…
-
NEJM published phase 2b clinical trial results demonstrating efficacy of COVID-19 vaccine against B.1.351 variant
On May 5, 2021, Novavax announced the publication of results from the initial primary analysis of a Phase…
-
Pfizer and BioNTech received Health Canada authorization of COVID-19 vaccine in adolescents
On May 5, 2021, Pfizer and BioNTech announced that Health Canada had expanded the Interim Order authorization for…
-
Hoth Therapeutics and Virginia Commonwealth University expanded research agreement for COVID-19 therapeutic
On May 5, 2021, Hoth Therapeutics announced it has expanded its sponsored research agreement with Virginia Commonwealth University…
-
Moderna announced expansion of its manufacturing technology center in Massachusetts
On May 4, 2021, Moderna announced an expansion of the Moderna Technology Center (MTC) in Norwood, MA including…
-
Moderna announced supply agreement with Gavi for up to 500 million doses of COVID-19 Vaccine Moderna for COVAX
On May 3, 2021, Moderna announced an agreement with Gavi, the Vaccine Alliance to supply up to 500…
-
Novavax initiated pediatric expansion for phase 3 clinical trial of COVID-19 vaccine
On May 3, 2021, Novavax announced that it had initiated a pediatric expansion of its Phase 3 clinical…
-
Gavi signed agreement with Moderna to secure doses on behalf of COVAX Facility
On May 3, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Moderna…
-
Moderna announced Emergency Use listing granted by the WHO for its COVID-19 vaccine
On Apr. 30, 2021, Moderna announced the World Health Organization (WHO) had listed the Moderna COVID-19 vaccine (mRNA…
-
Lonza and Moderna entered agreement to double drug substance production for COVID-19 vaccine in Visp
On Apr. 29, 2021, Lonza announced the expansion of its collaboration with Moderna to manufacture the drug substance…
-
NIH announced investment of $29 million to address COVID-19 disparities
On Apr. 29, 2021, the National Institutes of Health announced it was funding $29 million in ad itional…
-
Moderna announced an increased global supply for COVID-19 vaccine to up to 3 billion doses in 2022
On Apr. 29, 2021, Moderna announced it was making new funding commitments to increase supply at its owned…
-
CDC | COVID-19 | Infectious Disease | Vaccine
Fully vaccinated adults 65 and older are 94% less likely to be hospitalized with COVID-19
On Apr. 28, 2021, the Centers for Disease Control and Prevention (CDC) announced that both mRNA COVID-19 vaccines…
-
Biotechnology | COVID-19 | Disease | Infectious Disease | Oncology | Rare Disease | Therapeutics | Vaccine
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s…
-
INOVIO planned for ex-US global phase 3 trial for INO-4800
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
-
Tonix Pharma entered worldwide licensing agreement to develop antiviral SARS-CoV-2 inhibitor for treatment of COVID-19
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
-
Biotechnology | COVID-19 | Diagnostics | Genomics | Infectious Disease | Non-Profit Research | Therapeutics
Texas A&M lab identified new COVID-19 variant; genome suggested potential resistance to antibodies
On Apr. 19, 2021, scientists at the Texas A&M University Global Health Research Complex (GHRC) announced they had…
-
CytoDyn submitted Most Crucial Section of interim order to Health Canada for COVID-19 under rolling review
On Apr. 19, 2021, CytoDyn announced it had submitted the manufacturing section (CMC) of the application for an…
-
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
-
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had established a…
-
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
-
Biotechnology | Clinical Research | COVID-19 | FDA | HIV | Infectious Disease | Oncology | Therapeutics
CytoDyn executed agreement with Chiral Pharma to provide up to 200,000 vials of leronlimab to Philippines
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
-
Alternating vaccines trial expanded to include two additional vaccines
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
-
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
-
Moderna announced clinical progress from mRNA Vaccine
On Apr. 13, 2021, Moderna announced clinical and supply updates on its COVID-19 Vaccine program. New results from…
-
Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
-
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongly recommend…
